In patients achieving a best overall response (63%; n=25/40)

In the BR arm, 25% of patients achieved a best overall response at any time in the study, with 20% attaining a DoR ≥12 months and 30% attaining a DoR ≥6 months.

DoR was based on best overall response (BOR), which was defined as having a CR or PR at any time in the study. 3

Polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) is included in the NCCN Guidelines® as a preferred treatment option (Category 2A) based on the randomized, controlled GO29365 trial 1,2 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) as a preferred treatment option, after at least 2 prior therapies, for patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for transplant (Category 2A). 2

The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 27, 2020. To view the most recent and complete version of the guideline, go to NCCN.org.